Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Study
  • Published:

Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant

Nature Clinical Practice Oncology volume 4, pages 491–495 (2007)Cite this article

Abstract

Background A 19-year-old male with primary refractory acute myeloid leukemia received salvage therapy with mitoxantrone and cytarabine combination. He received consolidation therapy 3 months later with a matched-unrelated-donor stem-cell transplant. The disease relapsed in the bone marrow (BM) 9 months after the initial stem-cell transplant, and was successfully treated by repeat transplant from the same donor. Ten months following repeat transplant, the patient presented with an increasing number of extramedullary sites of biopsy-proven disease relapse (i.e. cranial and peripheral nerves, tongue, abdominal wall and chest wall). Repeated biopsy of the BM and chimera study showed no morphologic evidence of leukemic infiltrate with 100% donor-cell population.

Investigations Physical examination, complete blood count, BM biopsy, flow cytometry, cytogenetic analysis, chimera study, tongue biopsy, abdominal-wall biopsy, cytology and immunohistochemistry, CT scan of the chest, abdomen and pelvis, MRI of the brain, and cerebrospinal fluid analysis.

Diagnosis Isolated extramedullary relapse of acute myeloid leukemia after stem-cell transplant.

Management Primary leukemia treatment with idarubicin, cytarabine, etoposide, dexamethasone, tioguanine on protocol and salvage therapy with mitoxantrone and cytarabine combination for primary refractory disease. A matched-unrelated-donor stem-cell transplant for consolidation and donor-lymphocyte infusions were performed, followed by repeat unrelated-donor transplant for leukemia relapse in the marrow, radiation therapy and gemtuzumab ozogamicin for multiple sites of extramedullary leukemia relapse.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Biopsies of the masses obtained from the patient's abdominal wall and tongue
Figure 2: CT imaging of the chest of the patient before and after treatment with gemtuzumab ozogamicin

References

  1. Bekassy AN et al. (1996) Granulocytic sarcoma after allogeneic bone marrow transplantation: a retrospective European multicenter survey. Acute and Chronic Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 17: 801–808

    CAS  PubMed  Google Scholar 

  2. Au WY et al. (1999) Extra-medullary relapse of leukemia following allogeneic bone marrow transplantation. Hematol Oncol 17: 45–52

    Article  CAS  Google Scholar 

  3. Ruiz-Arguelles GJ et al. (2005) Extramedullary leukemic relapses following hematopoietic stem cell transplantation with nonmyeloablative conditioning. Int J Hematol 82: 262–265

    Article  Google Scholar 

  4. Simpson DR et al. (1998) High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem cell transplantation. Bone Marrow Transplant 22: 259–264

    Article  CAS  Google Scholar 

  5. Kara IO et al. (2005) Granulocytic sarcoma of the heart: extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone. Leuk Lymphoma 46: 1081–1084

    Article  Google Scholar 

  6. Choi SJ et al. (2004) Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse. Leukemia 18: 1789–1797

    Article  CAS  Google Scholar 

  7. Potenza L et al. (2006) Isolated extramedullary relapse after autologous bone marrow transplantation for acute myeloid leukemia: case report and review of the literature. Am J Hematol 81: 45–50

    Article  Google Scholar 

  8. Lee KH et al. (2003) Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course. Bone Marrow Transplant 32: 835–842

    Article  CAS  Google Scholar 

  9. Butcher EC et al. (1997) Lymphocyte homing and homeostasis. Science 272: 60–66

    Article  Google Scholar 

  10. Edinger M et al. (2003) CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9: 1144–1450

    Article  CAS  Google Scholar 

  11. Tsimberidou AM et al. (2006) The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol 132: 398–409

    CAS  PubMed  Google Scholar 

  12. Larson RA et al. (2005) Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104: 1442–1452

    Article  CAS  Google Scholar 

  13. Bross PF et al. (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7: 1490–1496

    CAS  PubMed  Google Scholar 

  14. Burnett AK et al. (2006) The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1,115 patients in the MRC AML15 trial [abstract #13]. Blood 108 (Suppl)

  15. Roman E et al. (2005) Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Clin Cancer Res 11 (Suppl): S7164–S7170

    Article  Google Scholar 

  16. Cohen AAD et al. (2002) Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplant 30: 23–28

    Article  CAS  Google Scholar 

  17. Piccaluga PP et al. (2004) Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas. Leuk Lymphoma 45: 1791–1795

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. T Owonikoko is a second-year Clinical Fellow in Hematology/Oncology, M Agha is the Clinical Director of the Stem Cell Transplantation Program, R Balassanian is Attending Pathologist, R Smith is Attending Radiation Oncologist and A Raptis is a Transplant Physician, all at the University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA, USA.,

    Taofeek Owonikoko, Mounzer Agha, Ronald Balassanian, Ryan Smith & Anastasios Raptis

Authors
  1. Taofeek Owonikoko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mounzer Agha
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ronald Balassanian
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ryan Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anastasios Raptis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anastasios Raptis.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Owonikoko, T., Agha, M., Balassanian, R. et al. Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant. Nat Rev Clin Oncol 4, 491–495 (2007). https://doi.org/10.1038/ncponc0899

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0899

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing